RAMP

Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024

Retrieved on: 
Tuesday, March 5, 2024

The presentations will highlight anti-tumor efficacy of GFH375 (VS-7375), a potent and selective orally bioavailable KRAS G12D (ON/OFF) inhibitor, and will also show data of RAF/MEK clamp plus FAK inhibition in pancreatic ductal adenocarcinoma (PDAC) models supporting the ongoing RAMP 205 trial.

Key Points: 
  • The presentations will highlight anti-tumor efficacy of GFH375 (VS-7375), a potent and selective orally bioavailable KRAS G12D (ON/OFF) inhibitor, and will also show data of RAF/MEK clamp plus FAK inhibition in pancreatic ductal adenocarcinoma (PDAC) models supporting the ongoing RAMP 205 trial.
  • Additional presentations will support the use of avutometinib and FAK inhibitor combination in cutaneous melanoma models to overcome resistance to BRAF and MEK inhibitors, resistance to immunotherapy, and brain metastasis.
  • “For the first time, GenFleet and Verastem will present potency, selectivity, anti-tumor efficacy, and bioavailability data on GFH375 (VS-7375), a potential best-in-class orally active KRAS G12D (ON/OFF) inhibitor.
  • We look forward to an IND submission by GenFleet in China in H1 2024,” said Jonathan Pachter, Ph.D., chief scientific officer of Verastem Oncology.

Hitachi High-Tech America, Inc. and Nabsys to collaborate through a "Rapid Application to Market Penetration User Partnership" Program to advance the OhmX Electronic Genome Mapping Platform

Retrieved on: 
Monday, February 5, 2024

PROVIDENCE, R.I., Feb. 5, 2024 /PRNewswire/ -- Hitachi High-Tech America, Inc. ("HTA"), in conjunction with Nabsys, announces a strategic leap forward in genomics research through HTA's planned acquisition of 50 OhmX instruments to support the joint "RAMP UP" program. RAMP UP, the Rapid Application to Market Penetration User Partnerships program, aims to propel cutting-edge electronic genome mapping technology into the hands of researchers for unparalleled whole genome structural variant analysis.

Key Points: 
  • The collaboration aims to continue to gain commercial traction after Nabsys announced the OhmX platform in October 2023.
  • RAMP UP, the Rapid Application to Market Penetration User Partnerships program, aims to propel cutting-edge electronic genome mapping technology into the hands of researchers for unparalleled whole genome structural variant analysis.
  • The platform leverages proprietary electronic nanochannel detectors to scan labeled high molecular weight DNA and perform de novo genome assembly for SV analysis.
  • For further information on Hitachi High-Tech's collaboration with Nabsys and the transformative OhmX platform, please visit www.nabsys.com .

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

Retrieved on: 
Monday, January 29, 2024

Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.

Key Points: 
  • Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today outlined key 2024 strategic priorities and upcoming catalysts to support advancement of its clinical programs in RAS pathway-driven cancers.
  • “We have made significant progress in our commitment to advancing new solutions for RAS pathway-driven cancers and look forward to an exciting and catalyst-filled year ahead.
  • Safety and tolerability continued to be favorable and consistent with previously reported data.
  • Entered into a discovery and development collaboration with GenFleet Therapeutics (“GenFleet”) to advance three oncology discovery programs targeting RAS pathway-driven cancers.

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

Retrieved on: 
Thursday, January 18, 2024

“Receiving Fast Track Designation for the combination of avutometinib and sotorasib reinforces the importance of improving the depth of MAPK pathway inhibition to enhance tumor regression relative to KRAS G12C inhibition alone and the potential of the combination of avutometinib and sotorasib in KRAS G12C mutant locally advanced or metastatic NSCLC,” said Dan Paterson, President and CEO, Verastem Oncology.

Key Points: 
  • “Receiving Fast Track Designation for the combination of avutometinib and sotorasib reinforces the importance of improving the depth of MAPK pathway inhibition to enhance tumor regression relative to KRAS G12C inhibition alone and the potential of the combination of avutometinib and sotorasib in KRAS G12C mutant locally advanced or metastatic NSCLC,” said Dan Paterson, President and CEO, Verastem Oncology.
  • “Given that KRAS G12C is the most common KRAS mutation in NSCLC, the advancement of the combination is important in understanding potential new treatment approaches.
  • The pharmacokinetic profile of avutometinib in combination with sotorasib in the RAMP 203 trial was similar to results in monotherapy studies.
  • These initial RAMP 203 results were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in October, 2023.

Data Center Solutions Market worth $591.7 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, January 24, 2024

By data center size, the mid-sized data center segment holds the second-largest market share during the forecast period.

Key Points: 
  • By data center size, the mid-sized data center segment holds the second-largest market share during the forecast period.
  • To optimize the use of servers, mid-sized data centers have a high use of virtualized environments, and efficient allocation of data center resources is required.
  • To facilitate high performance, efficient design, and easy deployment, these data centers are increasingly adopting data center transformation services.
  • Data Center Solutions Market Advantages:
    Organisations may effectively increase or contract their computer capabilities in response to demand thanks to the scalable architecture that data centre solutions offer.

Data Center Solutions Market worth $591.7 billion by 2028 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, January 24, 2024

By data center size, the mid-sized data center segment holds the second-largest market share during the forecast period.

Key Points: 
  • By data center size, the mid-sized data center segment holds the second-largest market share during the forecast period.
  • To optimize the use of servers, mid-sized data centers have a high use of virtualized environments, and efficient allocation of data center resources is required.
  • To facilitate high performance, efficient design, and easy deployment, these data centers are increasingly adopting data center transformation services.
  • Data Center Solutions Market Advantages:
    Organisations may effectively increase or contract their computer capabilities in response to demand thanks to the scalable architecture that data centre solutions offer.

Aspinity Welcomes Semiconductor Industry Veteran Richard Hegberg as CEO

Retrieved on: 
Wednesday, January 3, 2024

Aspinity , the leader in always-on processing and computation at near-zero power, announced today that is has appointed semiconductor industry leader Richard Hegberg as Chief Executive Officer.

Key Points: 
  • Aspinity , the leader in always-on processing and computation at near-zero power, announced today that is has appointed semiconductor industry leader Richard Hegberg as Chief Executive Officer.
  • Mr. Hegberg will drive Aspinity’s next phase of growth as its industry-leading AML100 processor enters volume production.
  • Mr. Hegberg joins Aspinity with strong leadership and management experience, and a proven track record of guiding companies through significant transition and growth periods.
  • Most recently, he was the CEO at Vesper Mems, where he helped lead the company to a successful acquisition.

Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Retrieved on: 
Wednesday, December 13, 2023

“Patients and treating physicians have advocated for more research and development in support of LGSOC.

Key Points: 
  • “Patients and treating physicians have advocated for more research and development in support of LGSOC.
  • At Verastem Oncology, we are moving with urgency to offer a Phase 3 study specifically directed at this disease in an effort to address this need,” said Dan Paterson, President and Chief Executive Officer, Verastem Oncology.
  • RAMP 301 is a global trial with enrollment open in the U.S. and planned enrollment in Canada, the United Kingdom, Europe, Australia, and Korea.
  • Dr. Grisham and Dr. Banerjee are paid consultants for Verastem Oncology.

System1 Announces Sale of Total Security

Retrieved on: 
Thursday, November 30, 2023

System1, Inc. (NYSE: SST) (“System1” or the “Company”), an omnichannel customer acquisition marketing platform, today announced the sale of Total Security Limited (“Total Security”) to a group led by Just Develop It Limited (the “Transaction”).

Key Points: 
  • System1, Inc. (NYSE: SST) (“System1” or the “Company”), an omnichannel customer acquisition marketing platform, today announced the sale of Total Security Limited (“Total Security”) to a group led by Just Develop It Limited (the “Transaction”).
  • The Transaction allows System1 to focus on its core advertising business and positions the Company for accelerated growth powered by its industry-leading Responsive Acquisition Marketing Platform (RAMP).
  • The Transaction also enhances the Company’s financial profile and leverage position, while providing greater financial flexibility to fuel its future growth.
  • “The sale of Total Security represents System1’s commitment to providing our world-class RAMP technology to powerful brands and delivering high-quality consumers to our advertising partners,” said Michael Blend, System1’s Co-Founder, Chairman & Chief Executive Officer.

Fetch Named to Fast Company's Third Annual List of the Next Big Things in Tech

Retrieved on: 
Tuesday, November 28, 2023

MADISON, Wis., Nov. 28, 2023 /PRNewswire/ -- Fetch, the nation's No. 1 consumer-rewards app and leading consumer-engagement platform, today announced that it has been named to Fast Company's third-annual Next Big Things in Tech list, honoring technology breakthroughs that promise to shape the future of industries—from healthcare and security to artificial intelligence and data.

Key Points: 
  • Fast Company highlighted Fetch in the Marketing and Advertising category for the development of its proprietary measurement methodology, Verified Incremental Return (VIR).
  • "At a time when commerce and advertising are undergoing massive changes, Fetch is reshaping how brands and consumers connect," said Fetch CEO & Founder, Wes Schroll.
  • "The Next Big Things in Tech is not just a look around the corner—it's a look around the corner after that," says Brendan Vaughan, editor-in-chief of Fast Company.
  • The Winter 2023/2024 issue of Fast Company is available online now and will hit newsstands on December 5.